NCT04262141

IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

Investigator-Initiated Trial of the LSD1 Inhibitor IMG-7289 for the Treatment of Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) That Have Failed at Least One Standard Therapy

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Terrence J Bradley, MD · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the hematologic effects of IMG-7289 therapy in ET and PV patients who require platelet, White Blood Cell (WBC) or Red Blood Cell (RBC) control, and have failed at least one standard therapy.

Conditions

• Essential Thrombocythemia
• Polycythemia Vera

Interventions

Type	Name	Description
DRUG	IMG-7289	Daily oral dose of 0.6 mg/kg/day IMG-7829 capsules. Dose escalation an de-escalation rules applied as necessary.

Timeline

• Start date: 2020-10-02
• Primary completion: 2026-10-31
• Completion: 2027-10-31
• First posted: 2020-02-10
• Last updated: 2026-01-07

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study